Thursday, June 17, 2021
Times of Georgia
HomeWorldCAPA-IVM A Promising Advance In Assisted Reproduction For Women With PCOS

CAPA-IVM A Promising Advance In Assisted Reproduction For Women With PCOS

SINGAPORE, May 10, 2021 /PRNewswire/ — The first births
and on-going well-being of babies born from an advanced
assisted reproduction process called CAPA in-vitro oocyte
maturation, or IVM, has highlighted the potential of the
procedure for millions of women with complex fertility
issues including polycystic ovarian syndrome

IVM is a technique to obtain oocytes that are
developed in vitro prior to fertilisation with sperm in a
laboratory with an embryo transferred back into a patient’s
uterus with the aim of an ongoing pregnancy and live

A major benefit of IVM is that it requires
minimal hormonal stimulation of the ovaries that is a
standard protocol in traditional IVF. Hormonal stimulation
in IVF can cause a debilitating and potentially
life-threatening condition known as ovarian hyperstimulation
syndrome, or OHSS, in women with PCOS.

IVM is also an
option for women of reproductive age facing cancer treatment
because conventional IVF hormone treatment can also
stimulate cancer cells in estrogen-sensitive

CAPA-IVM is a relatively new protocol using
an advanced culture medium that improves the in vitro
development of immature oocytes potentially resulting in a
higher number of quality embryos per patient.

At the
10th Congress of the Asia Pacific Initiative on Reproduction
(ASPIRE), the latest data on CAPA-IVM births and the health
of babies born from the protocol has been presented with
encouraging outlooks.

ASPIRE is a unique task force of
clinicians and scientists involved in the management of
fertility and assisted reproductive technology (ART)
throughout the Asia Pacific region. The ASPIRE Congress is
being presented in virtual format –
– to fertility specialists in over 100

Associate Professor Dr Lan N Vuong, a
pioneer in assisted reproduction in Vietnam and Head of the
Department of Obstetrics and Gynaecology at the University
of Medicine and Pharmacy at Ho Chi Minh City, said several
variants of IVM had been used successfully as an alternative
to standard IVF in different patients groups with variable
success rates.

However, she said IVM had not gained
widespread acceptance even though it avoids or minimises
controlled ovarian stimulation, reduces medication costs and
results in shorter treatment periods with improved
psychological burden on patients.

“The most important
and relatively recent advance in IVM technology is the
CAPA-IVM protocol using a new compound to facilitate oocyte
and embryo competence.

“Our group at the My Duc
Hospital in Ho Chi Minh City recently reported the first
live births resulting from CAPA-IVM with a clinical
pregnancy rate per embryo transfer of 63.2 per cent compared
with 38.5 per cent from standard IVM.

“The live birth
rate per embryo transfer was not statistically different
between the CAPA-IVM and standard IVM groups, birth weights
were similar in the two treatment groups and there were no
reported malformations.”

Dr Vuong’s group has also
undertaken the first large randomised control trial
comparing the fertility, obstetrics and neonatal outcomes of
CAPA-IVM and conventional IVF with no significant
differences in obstetric outcomes including gestational age
at delivery.

“There is a current and continuing focus
on the health and development of babies born from this
technology, but the American Society of Reproductive
Medicine recently reported that IVM is no longer considered
experimental,” she said.

“We therefore consider that
CAPA-IVM could improve outcomes for particular groups of
women, including those with PCOS, who are seeking treatment
for infertility.”

Source : ASPIRE 2021 Virtual

© Scoop Media


Source link

- Advertisment -
Times of Georgia Times of Georgia Times of Georgia

Most Popular